CSIMarket Company Name, Ticker, Competitors, else..
 
Cybin Inc   (NYSEAMER: CYBN)
Other Ticker:  
 
 
Price: $7.3700 $-0.15 -1.995%
Day's High: $7.6 Week Perf: -2.64 %
Day's Low: $ 7.28 30 Day Perf: -20.92 %
Volume (M): 97 52 Wk High: $ 13.88
Volume (M$): $ 718 52 Wk Avg: $9.68
Open: $7.49 52 Wk Low: $6.50



 Market Capitalization (Millions $) 61
 Shares Outstanding (Millions) 8
 Employees 30
 Revenues (TTM) (Millions $) 71
 Net Income (TTM) (Millions $) -60
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 0

Cybin Inc


   Company Address: 100 King Street West Toronto 0 ON
   Company Phone Number: 764-8385   Stock Exchange / Ticker: NYSEAMER CYBN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADIL        3.62% 
ALZN        44.46% 
ANRO   -15.14%    
ATAI   -7.43%    
LSB        2.5% 
SAGE        3.76% 
• View Complete Report
   



Acelyrin Inc

In the fiscal period ending fourth quarter of 2024 operating shortfall illustrated progress to $-105.112 million, at the Major Pharmaceutical Preparations company

The Major Pharmaceutical Preparations sector contributors begin to analyze the fourth quarter of 2024 earnings. Presently those contributors monitor operating shortfall of $-85.712 million, from the company, as it has not mentioned any revenue thus far, for the respective October to December 31 2024 reporting season.

Avalo Therapeutics Inc

Severe hit for the company amid the fourth quarter of 2024 earnings season

For the October to December 31 2024 span company decreased a loss per share of $-1.51 per share compare to $-8.50 a year before and earnings per share improved from $-2.83 per share from the prior reporting period. The revenue fell sharply by -66.316 % to $0.19 million from $0.57 million in the corresponding reporting period a year before and sequentially revenue fell by -22.892 % from $0.25 million.

Precigen Inc

Observing the fourth quarter of 2024 performance, the company's experienced

Directing the attention towards the October to December 31 2024 time-frame PGEN decreased a loss per share at $-0.07 per share, relative to the recent numbers of $-0.13 per share a year ago financial reporting period, In the previous financial reporting period PGEN realized $-0.09 per share.

Ars Pharmaceuticals Inc

Ars Pharmaceuticals Inc announced Revenue of $86.581 million, in the Dec 31 2024 report

the Major Pharmaceutical Preparations company has seen $86.581 million, in Revenue in the fourth quarter of 2024.

Scpharmaceuticals Inc

Scpharmaceuticals Inc disclosed that revenue comparatively doubled, during the October to December 31 2024 span

For the fourth quarter of 2024 SCPH Deficit has swelled of $-0.31 per share compare to $-0.28 a year ago and earnings per share improved from $-0.75 per share from the previous reporting period. The revenue rose strongly by 99.311 % to $12.15 million from $6.10 million in the comparable reporting period a year ago and sequentially revenue improved by 21.185 % from $10.03 million. SCPHs' has clearly exceeded its sector contemporaries on the top-line angle, as the Major Pharmaceutical Preparations sector report 11.88% during the same period revenue improvement thus far.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com